Medicus Pharma MDCX

Medicus Pharma Ltd. is a clinical stage multi-strategy biotechnology company focused on advancing novel therapeutic assets through Phase 2 proof-of-concept studies with the goal of pursuing out-licensing or strategic partnerships with established pharmaceutical companies best positioned to conduct late-stage development and commercialization. The company operates across three continents and opportunistically identifies evaluates acquires and in-licenses accretive assets and businesses in the oncology and dermatology therapeutic areas.

Medicus Pharma Ltd. generates revenue primarily through potential future out-licensing deals strategic partnerships and milestone payments associated with the clinical development of its therapeutic candidates. The company does not currently commercialize any products and therefore does not generate product sales revenue at this stage of its development.

The company operates through the following segments: SkinJect and Antev.

• SkinJect is a clinical stage biotech company developing doxorubicin containing microneedle arrays (D-MNA) a novel localized immunogenic precision therapy focused on non-melanoma skin diseases especially basal cell carcinoma (BCC) representing approximately $2 billion in potential market opportunity. The D-MNA product candidate is a drug device combination regulated under an Investigational New Drug Application #139837 with the Center for Drug Evaluation and Research Oncology Division. SkinJect has completed Phase 1 clinical testing demonstrating safety and tolerability and is currently conducting Phase 2 studies in the United States and United Arab Emirates to evaluate efficacy in nodular BCC patients.

• Antev is a clinical stage biotech company developing Teverelix a next generation gonadotrophin-releasing hormone (GnRH) antagonist potentially as a first in market product for advanced prostate cancer patients with high cardiovascular risk and patients with acute urinary retention relapse due to enlarged prostate collectively representing approximately $6 billion in potential market opportunity. Teverelix is formulated as a microcrystalline suspension allowing for sustained release and a six-week dosing interval. Antev has completed Phase 1 and Phase 2a studies and has received FDA approval for Phase 2b study designs in both advanced prostate cancer and acute urinary retention indications.

Medicus Pharma Ltd. positions itself as an innovative developer of differentiated therapeutic candidates leveraging novel drug delivery technologies and mechanistically distinct approaches to address underserved patient populations. The company competes with other biotechnology firms developing topical and injectable therapies for skin cancer and hormone modulators for prostate cancer but differentiates itself through its microneedle array platform for SkinJect and the cardiovascular risk mitigating profile of Teverelix for Antev. The company's competitive advantages include its exclusive global license to microneedle array technology from the University of Pittsburgh and its intellectual property portfolio covering Teverelix composition and delivery methods with patents extending to 2039 and beyond.

Medicus Pharma Ltd. serves patients suffering from basal cell carcinoma Gorlin Syndrome advanced prostate cancer with cardiovascular risk and acute urinary retention episodes. The company's therapeutic candidates are intended for use by dermatologists oncologists and urologists in clinical settings subject to physician supervision and potential future reimbursement by healthcare systems and third-party payors.